These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20007955)

  • 81. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
    Yoo DH; Hrycaj P; Miranda P; Ramiterre E; Piotrowski M; Shevchuk S; Kovalenko V; Prodanovic N; Abello-Banfi M; Gutierrez-Ureña S; Morales-Olazabal L; Tee M; Jimenez R; Zamani O; Lee SJ; Kim H; Park W; Müller-Ladner U
    Ann Rheum Dis; 2013 Oct; 72(10):1613-20. PubMed ID: 23687260
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
    Mukherjee A; Tsuchiwata S; Nicholas T; Cook JA; Modesto I; Su C; D'Haens GR; Sandborn WJ
    Clin Pharmacol Ther; 2022 Jul; 112(1):90-100. PubMed ID: 35380740
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera.
    Beeg M; Burti C; Allocati E; Ciafardini C; Banzi R; Nobili A; Caprioli F; Garattini S; Gobbi M
    Sci Rep; 2021 Jul; 11(1):14976. PubMed ID: 34294782
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Resolution of inflammation: from basic concepts to clinical application.
    Neurath MF
    Semin Immunopathol; 2019 Nov; 41(6):627-631. PubMed ID: 31776733
    [No Abstract]   [Full Text] [Related]  

  • 85. A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies.
    Beeg M; Nobili A; Orsini B; Rogai F; Gilardi D; Fiorino G; Danese S; Salmona M; Garattini S; Gobbi M
    Sci Rep; 2019 Feb; 9(1):2064. PubMed ID: 30765716
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Current and emerging therapeutic targets for IBD.
    Neurath MF
    Nat Rev Gastroenterol Hepatol; 2017 May; 14(5):269-278. PubMed ID: 28144028
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Infliximab-induced thrombocytopenia in a patient with ulcerative colitis.
    Matsumoto S; Mashima H
    Int J Colorectal Dis; 2016 Apr; 31(4):921-2. PubMed ID: 26149944
    [No Abstract]   [Full Text] [Related]  

  • 88. Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases.
    Malíčková K; Ďuricová D; Bortlík M; Janatková I; Zima T; Lukáš M
    Auto Immun Highlights; 2013 Apr; 4(1):27-32. PubMed ID: 26000139
    [TBL] [Abstract][Full Text] [Related]  

  • 89. New targets for mucosal healing and therapy in inflammatory bowel diseases.
    Neurath MF
    Mucosal Immunol; 2014 Jan; 7(1):6-19. PubMed ID: 24084775
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
    Nanda KS; Cheifetz AS; Moss AC
    Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.
    Shah B; Mayer L
    Expert Rev Clin Immunol; 2010 Jul; 6(4):607-20. PubMed ID: 20594134
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comment on 'Predicting the response to infliximab from trough serum levels'.
    Bendtzen K; Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J
    Gut; 2010 Sep; 59(9):1298-9; author reply 1299-300. PubMed ID: 20801776
    [No Abstract]   [Full Text] [Related]  

  • 93. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
    Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
    Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Infliximab in ulcerative colitis.
    Böcker U
    Scand J Gastroenterol; 2006 Sep; 41(9):997-1000. PubMed ID: 16938710
    [No Abstract]   [Full Text] [Related]  

  • 96. Predicting the response to infliximab from trough serum levels.
    Rutgeerts P; Vermeire S; Van Assche G
    Gut; 2010 Jan; 59(1):7-8. PubMed ID: 20007955
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.